Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Jan 01, 2007 (Vol. 27, No. 1)


  • Interesting philosophy
  • Not overly informative
Taking the position that “wrongly issued patents and unsound patent policy harm the public,” PUBPAT from the Public Patent Foundation claims to represent the public’s interests in the patent system. Goodness knows that someone needs to do it. The organization has had some notable successes, including revocation of a patent that would have affected use of JPEG images on computers and revocation of a patent to Pfizer for the drug lipitor. The not-for-profit group aims to recapture ideas back to the public domain that were removed from the same by mis-issued patents. Given the amount of money behind many of the software and pharmaceutical patents, this is no small order. The group’s major victories have come as a result of showing the existence of prior art, and this too is no small task in at least some cases. An interesting group with an interesting focus, PUBPAT probably has a lot of friends as well as a lot of enemies.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »